Current Challenges in Personalized Cancer Medicine, Vol 65. Advances in Pharmacology

  • ID: 2484329
  • Book
  • 576 Pages
  • Elsevier Science and Technology
1 of 3

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.

  • Brought together some of the foremost basic science and clinical researchers
  • Part of the renowned Advances in Pharmacology Serial
  • Discussion of some of the new frontiers in the development of targeted cancer therapy

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3
  1. Vertical pathway targeting in cancer therapy
  2. Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors
  3. Targeting the tumor stroma as a novel treatment strategy for breast cancer
    shifting from the neoplastic cell-centric to a stroma-centric paradigm
  4. Targeting the Metabolic Microenvironment of Tumors
  5. Targeted Therapy for Matastasis
  6. Emerging Strategies for Targeting Cell Adhesion in Multiple Myelom
  7. Targeting Notch Signaling for Cancer Therapeutic Intervention
  8. Stem-like cells and therapy resistance in squamous cell carcinomas
  9. Targeting the tumor stroma as a novel therapeutic approach for prostate cancer
  10. Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations
  11. Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations
  12. Chemoprevention of Melanoma
  13. Whole genome and exome sequencing of melanoma: a step toward personalised targeted therapy
  14. Targeted Therapy for Gastric Adenocarcinoma
  15. HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
  16. Apoptosis in Targeted Therapy Responses: The Role of BIM
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll